stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Return on equity
Fortrea Holdings Inc.'s return on equity over the twelve months to 30 September 2026 was −12.3%, up 90.1 percentage points from fiscal 2025 (−102.4%). Over the past ten years it has ranged from −102.4% (fiscal 2025) to 5.64% (fiscal 2022) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −52.0% and above the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −102.4% | (81.05) |
| FY2024 | −21.4% | (20.36) |
| FY2023 | −1.00% | (6.64) |
| FY2022 | 5.64% | 5.64 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| HRMY Harmony Biosciences Holdings, Inc. compare | 18.7% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| SRPT Sarepta Therapeutics, Inc. compare | −8.05% |
| FTRE Fortrea Holdings Inc. | −12.3% |
| VIR Vir Biotechnology, Inc. compare | −21.8% |
| IMNM Immunome, Inc. compare | −64.0% |
| ZYME Zymeworks Inc. compare | −72.3% |
| REPL Replimune Group, Inc. compare | −115.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)